Arpit Davé Joins BioMarin as Chief Digital and Information Officer
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has recently welcomed Arpit Davé to its executive team as the Chief Digital and Information Officer. In this newly established role, he will be directly reporting to BioMarin's President and CEO, Alexander Hardy. Mr. Davé is set to spearhead the transformation of the company's enterprise technology strategy, focusing on data science and digital innovation to generate tangible value for patients, employees, and stakeholders.
Mr. Davé's Background and Experience
With over 20 years of rich experience in information technology and artificial intelligence specifically within the biopharmaceutical sector, Mr. Davé is known for his ability to drive organizations towards patient-centric solutions that boost growth and profitability. Prior to joining BioMarin, he served as a technology executive with Amgen, Inc., where he has cultivated a substantial knowledge in digital transformation initiatives. His leadership at Amgen centered on implementing AI and digital technologies aimed at enhancing the company’s competitive edge in a rapidly evolving marketplace.
His career also includes significant roles at Bristol Myers Squibb and Merck, where he was deeply involved in CIO leadership, data science, as well as research and development. Mr. Davé received his M.S. in Industrial Engineering from the University of Texas and a B.S. in Mechanical Engineering from S.P. University in India.
Vision for BioMarin's Future
Mr. Hardy praised Mr. Davé for his visionary approach, expressing confidence in his capability to leverage technology to drive substantial benefits for BioMarin and the patients it serves. “Arpit is a visionary thinker and a talented leader, he will be building a strategic vision and roadmap,” noted Hardy, emphasizing the importance of technology in enhancing business operations across all facets of the organization.
Commitment to Patients
In his statement, Mr. Davé articulated his admiration for BioMarin's unwavering commitment to individuals living with rare diseases. He expressed excitement about collaborating with the team to provide considerable value for the patients, employees, and investors. His focus will be on harnessing the intersection of biology, data, and AI to unlock fast insights and expedite the delivery of transformative therapies, significantly benefiting those who rely on BioMarin’s innovations.
About BioMarin Pharmaceutical Inc.
BioMarin is a leading and globally recognized biotechnology firm dedicated to the development of groundbreaking therapies for rare genetic conditions. Established in 1997, this company has shown a proven dedication to innovation and currently offers eight commercial therapies alongside a robust pipeline of clinical and preclinical projects.
The company’s distinctive strategy for drug discovery and development aims to maximize the potential of genetic science by creating transformative medicines that significantly improve patient outcomes. BioMarin continues to push the boundaries to offer novel solutions for those facing rare diseases.
Contact Information
Inquiries regarding BioMarin may be directed to:
Investors
Traci McCarty, BioMarin Pharmaceutical Inc. - (415) 455-7558
Media
Erin Rau, BioMarin Pharmaceutical Inc. - (925) 683-9622
Frequently Asked Questions
Who is Arpit Davé?
Arpit Davé is the newly appointed Chief Digital and Information Officer at BioMarin, bringing over two decades of experience in digital transformation and technology.
What role will Mr. Davé play at BioMarin?
He will be responsible for reimagining the enterprise technology strategy, focusing on digital transformation to maximize value for patients and stakeholders.
Where did Arpit Davé previously work?
Prior to BioMarin, Mr. Davé worked at Amgen, Inc., where he was a technology executive involved in driving digital transformation efforts.
What is BioMarin known for?
BioMarin is renowned for its commitment to developing innovative medicines for rare diseases and its strong pipeline of therapies.
How can I contact BioMarin?
You can reach out to them through their investor relations or media contacts listed above for further inquiries.
